Neurology:帕金森病患者的运动和非运动症状与健康相关的生活质量的关系

2022-06-09 MedSci原创 MedSci原创

潜在的可治疗的运动和非运动症状,特别是神经精神症状,在PwPD的HRQOL的变化中占了很大一部分。

人们对健康相关的生活质量(HRQOL)越来越感兴趣,认为它是对病人福祉的全面展现,是治疗的临床医生的指导概念,也是帕金森病患者(PwPD)的治疗试验结果测量。HRQOL的关键决定因素尚未在大量的PwPD人群中进行调查。为此,来自美国的学者开展了一项在一个大型的帕金森病患者在线队列中评估HRQOL的相关因素的研究。

作为正在进行的在线队列研究的一部分,研究人员对23058名PwPD进行了注册时的横断面分析。对EQ-5D-5L工具测量的HRQOL进行了单变量和逐步多变量的线性回归分析。此外,还进行了交互分析以评估运动症状对HRQOL影响的异质性,并进行了Spearman相关分析以评估非运动症状与HRQOL的关系。

结果显示,在多变量线性回归模型中,有中度或重度抑郁症、更严重的运动症状和更高的合并症负担的参与者,用EQ指数测量的HRQOL下降最多(分别为β-0.11、-0.18、-0.02、-0.01;所有P<0.001)。交互分析显示,更严重的运动症状对女性、低教育水平、低收入、更严重的抑郁症或更严重的认知障碍的人有更大的影响(交互项的p≤0.01)。神经精神症状和跌倒与HRQOL有最大的负相关(ρ -0.31至0.37;p < 0.0001)。

潜在的可治疗的运动和非运动症状,特别是神经精神症状,在PwPD的HRQOL的变化中占了很大一部分。在不同的人口统计学和临床亚群中,运动症状可能对HRQOL有不同的影响,突出了未来健康差异研究的重要领域。

 

参考文献:

Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease.Neurology May 2022, 98 (22) e2194-e2203; DOI: 10.1212/WNL.0000000000200113

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-09-01 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-06-09 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]

相关资讯

iPSC疗法、新靶点、单细胞测序,帕金森病最新研究进展解读

帕金森病的治疗和诊断一直是十分热门的研究领域,最近帕金森病领域有了一些新的突破。通过这篇文章,我们一起了解下帕金森病领域的一些新发现、新进展。

Movement Disorders:路易体病理和阿尔兹海默病理,如何影响男女的临床表型差异?

使用LB和AD生物标志物,即使在LB或AD病理不在临床预期之内,对于LB疾病和AD的准确临床诊断也是必要的。

Movement Disorders:特发性帕金森病患者尿液中Rab10磷酸化的升高

pT73-Rab10的水平较高与疾病进展的恶化有关。

European Radiology:帕金森病的SMwI MRI前瞻性多中心研究

最近,临床上开发了感光图加权成像(SMwI)技术以改善描绘含铁结构的信噪比和对比度-噪声比。最近的研究进一步表明,SMwI在评估3T下的黑质高浓度方面优于SW。

Movment Disorders:帕金森氏征,7T MRI蓝斑核完整性与帕金森病患者的冷漠和认知有关

去甲肾上腺素能治疗策略在解决神经退行性疾病的跨诊断认知和行为特征方面有潜力。

拓展阅读

AAN 2024:突触核蛋白皮肤活检在帕金森病的初步诊断的临床实践

帕金森病早期准确诊断是一项尚未满足的重大需求,这对于早期干预和预后改善有着重要的影响。

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。

European Radiology:弥散基础频谱成像检测早期帕金森病黑质和白质束的病理改变

为了解决弥散张量成像的局限性,研究发展了弥散基谱成像 (DBSI)以粗量化各向异性扩散张量反映轴突的完整性,其在多种中枢神经系统疾病中的敏感性和准确性已被证实。

帕金森病睡眠量表修订版(PDSS-2)

帕金森病睡眠量表修订版(PDSS-2)